At 50, Tylenol brand gaining steam on safety image


Published: Tuesday, November 1, 2005 at 6:01 a.m.
Last Modified: Tuesday, November 1, 2005 at 12:32 a.m.
TRENTON, New Jersey - Tylenol, originally a pain reliever for children, has hit middle age.
The world's best-known acetaminophen brand turns 50 on Tuesday, and it's more popular than ever, in part because of its reputation as the safest nonprescription pain reliever. Even a fatal 1982 poisoning scare barely hurt the brand - and introduced tamperproof packaging.
Already in medicine cabinets in 70 percent of U.S. households, Tylenol now is seeing sales jump amid concern over the risks of other painkillers. Sales have grown by double digits since last fall, according to Tylenol maker McNeil Consumer & Specialty Pharmaceuticals.
''It's become the fastest-growing pain reliever in 2005,'' said Ashley A. McEvoy, general manager of McNeil Consumer, part of health care conglomerate Johnson & Johnson.
Tylenol sales are up about 9 percent in 2005's first nine months, after holding or declining slightly the three years before, according to Chicago market research firm Information Resources Inc. Sales last year totaled $786.5 million (euro 654.16 million), but IRI doesn't track sales to hospitals, nursing homes or Wal-Mart stores.
One reason for growing sales is that since September 2004, popular prescription painkillers Vioxx and Bextra were pulled from the market because of increased risk of heart attack and stroke.
Earlier this year, the Food and Drug Administration warned other anti-inflammatory drugs carry such risks.
Tylenol is in a separate drug class from anti-inflammatories such as Vioxx, ibuprofen and naproxen. Compared with those drugs and aspirin, Tylenol is less likely to interact with other medications, irritate the stomach or cause internal bleeding, and its safe for patients with common conditions such as heart disease and diabetes.
''Doctors and patients are confident they won't have these kinds of complications,'' said Dr. Michel Dubois, director of research at the New York University Pain Management Center. ''That's why it has been so popular.''
Dubois said despite J&J's aggressive marketing, Tylenol is not the best choice for arthritis pain because it does not reduce inflammation. It also has a rare risk of liver damage at very high doses.
A Harvard study released in August also found that Tylenol increased the risk of blood pressure problems on women. The research - which involved 5,123 women participating in the Nurses Health Study at Harvard Medical School and Brigham and Women's Hospital in Boston - found that aspirin still remains the safest medicine for pain relief.
Acetaminophen had been used in Europe since 1893, but was little known in the United States when the Tylenol brand was launched in 1955. McEvoy said Tylenol was the first aspirin-free, non-narcotic pain reliever on sale in the country - only available by prescription, for children and in liquid form. McNeil, acquired by Johnson & Johnson in 1959, rolled out the first Tylenol for adults in 1961.
Tylenol's biggest challenge, the 1982 cyanide tampering scare in Chicago that killed seven people, is considered ''a case study of how to deal with a brand crisis,'' said Mark Bard, president of Manhattan Research. He said pharmaceutical companies such as Vioxx maker Merck & Co. and Bextra maker Pfizer Inc. ''could learn some lessons from what happened 20 years ago.''
J&J had its sales force remove 264,000 Tylenol bottles from Chicago area stores; consumers also were urged to return any Tylenol they had for a safe bottle, and prompt alerts from J&J and the FDA kept the public informed, recalled Dr. Anthony Temple, head of medical affairs for McNeil Consumer in 1982.
''If you leave people in the dark, you have a real risk of them never being able to trust you'' again, said Temple, now senior medical consultant for McNeil Consumer. It took just a few months to regain public confidence, he said.
Bard said it was worth it for Johnson & Johnson to spend around $100 million (euro 83.17 million) on the recall to save its brand, given that nonprescription drugs are on the market for decades, compared with prescription drugs that lose patent protection, and thus most of their sales, in 10 to 15 years at most.
The culprit was never caught, but McNeil prevented a recurrence by developing containers protected by multiple seals.
''They made tamperproof packaging, which we take for granted today'' on everything from nonprescription drugs to pickle jars, Bard said.
''If you leave people in the dark, you have a real risk of them never being able to trust you''

Reader comments posted to this article may be published in our print edition. All rights reserved. This copyrighted material may not be re-published without permission. Links are encouraged.

Comments are currently unavailable on this article

▲ Return to Top